3月4日，据CDE官网消息，浙江海昶生物医药技术有限公司联合申请药品“HC016脂质复合物注射液”，获得临床试验默示许可，受理号CXHL2401413。
公示信息显示，药品“HC016脂质复合物注射液”适应症： 拟用于晚期或复发性实体瘤，包括黑色素瘤、头颈部鳞状细胞癌、肉瘤（包括骨肉瘤、尤文氏肉瘤、横纹肌肉瘤、滑膜肉瘤、恶性周围神经鞘瘤、黏液/圆细胞脂肪肉瘤）。
浙江海昶生物医药技术有限公司，成立于2013年，位于杭州市，是一家以从事科技推广和应用服务业为主的企业。企业注册资本3134.7986万人民币，实缴资本2943.29276万人民币。
通过天眼查大数据分析，浙江海昶生物医药技术有限公司共对外投资了6家企业，参与招投标项目59次，知识产权方面有商标信息10条，专利信息18条，此外企业还拥有行政许可18个。
主要股东信息显示，浙江海昶生物医药技术有限公司由上海玛珠生物科技有限公司持股22.4809%、国投（上海）科技成果转化创业投资基金企业（有限合伙）持股8.1431%、杭州齐众医药投资合伙企业（有限合伙）持股7.8059%、赵孝斌持股6.1835%、浙江昂利康制药股份有限公司持股5.6201%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.